BioSpace News Archive

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020

Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter ended March 31, 2020 and provided an update on its product pipeline and corporate activities.

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced positive topline results from the signal-finding Phase 2 ROCKET trial of OV101, a novel delta -selective GABAA receptor agonist, in males with Fragile X syndrome.

ADMA Biologics, Inc. announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020.

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

OPTI Medical Systems, Inc. announced that the United States Food and Drug Administration has granted Emergency Use Authorization for the OPTI® SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19.

GenScript USA announced it is collaborating with Avidea Technologies on a presentation at the SelectScience® Virtual Summit on Cancer and Immunology Research 2020, taking place May 11-13.

Palatin Technologies, Inc. will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets.

Includes screening recommended in early pregnancy, as well as cancer risk assessment, guided by telehealth clinicians and completed at home